Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket

GeneDx reported quarterly losses of 33 cents per share which beat the analyst consensus estimate of losses of 67 cents. The company reported quarterly sales of $62.422 million which beat the analyst consensus estimate of $49.463 million, according to data from Benzinga Pro.

GeneDx raised its full-year 2024 revenue guidance to between $235 million and $245 million, up from $220 million to $230 million, and expanded its full-year 2024 adjusted gross margin profile to at least 60% from at least 50%.

GeneDx Holdings shares climbed 37.4% to $15.11 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

Losers

Now Read This: Coca-Cola, Amazon And 3 Stocks To Watch Heading Into Tuesday

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.